Combretastatin A4

For research use only. Not for use in humans.

目录号:S7783 中文名称:康普立停 A4

Combretastatin A4 Chemical Structure

CAS No. 117048-59-6

Combretastatin A4 是一种以 microtubule 为靶点的试剂,其与β-微管蛋白结合,Kd 为 0.4 μM。Phase 3。

规格 价格 库存 购买数量  
RMB 811.66 现货
RMB 3258.32 现货
RMB 8166.98 现货
有超大折扣
今日订购,明日送达 全国免运费 分装免费
全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Combretastatin A4发表文献3篇:

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Combretastatin A4 是一种以 microtubule 为靶点的试剂,其与β-微管蛋白结合,Kd 为 0.4 μM。Phase 3。
靶点
β-tubulin [1]
0.4 μM(Kd)
体外研究

Combretastatin A4抑制MDA-MB-231,A549,Hela,HL-60,SF295,HCT-8,MDA-MB435,PC3M,OVCAR-8,NCI-H358M,和淋巴细胞的生长,IC50分别为2.8,3.8,0.9,2.1,6.2,5.3,7.9,4.7,0.37,8,和3.2 nM。[1] [2]1 μM Combretastatin A4抑制35%微管蛋白聚合,10 μM几乎完全阻断微管蛋白聚合。Combretastatin A4表现出高的相对结合能力,达到秋水仙碱结合力的78%。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 MkPpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWfXbmFYS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hW0uPRVytOUBu\Wyjbn;tZUBk\WyuIHzpcoV{NCCHREWwQVMvODCHLUC4JO69VQ>? MXOxPFc2OzVy
A-549 M2XhVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoDFR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gRU02PDlibIXu[{Bk[XKlaX7vcYEh[2WubDDsbY5meyxiRVS1NF0yNjJyRT2wOkDPxE1? NFzFVlUyQDd3M{Ww
MCF-7 MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnWeY1rS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hVUOILUegZpJm[XO2IHPhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUOuPFBGNTB4IN88US=> MYWxPFc2OzVy
HT-29 NEW2SG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1vwbmN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJGhVNTJ7IHPvcI9vKGGmZX7vZ4Fz[2mwb33hJINmdGxibHnu[ZMtKEWGNUC9NU4zOEVvME[g{txO NGixSXkyQDd3M{Ww
MLM melanoma cell Mor0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVvDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDNUG0hdWWuYX7vcYEh[2WubDDsbY5meyxiRVS1NF0yNjRyRT2wOkDPxE1? MoTJNVg4PTN3MB?=
M14 MVrDfZRwfG:6aXPpeJkh[XO|YYm= M4\Pc2lvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB4[XNidHXzeIVlKGGpYXnud5QhcHWvYX6gcYVt[W6xbXGgZ4Fv[2W{IDjNNVQqKGOnbHygcIlv\SxiR1m1NF0xNjByMEGg{txO NEWwPWsyOjd{OU[0NC=>
SK-OV3 NYrvR3RJS3m2b4TvfIlkcXS7IHHzd4F6 MlfXTY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJRme3SnZDDh[4FqdnO2IHj1cYFvKG:4YYLpZY4h[2GwY3XyJEhUUy2RVkOpJINmdGxibHnu[UwhT0l3ME2wMlAxODFizszN NViwR4xkOTJ5Mkm2OFA>
HL60 cells MVnDfZRwfG:6aXPpeJkh[XO|YYm= NW\4UIVPPzJiaB?= MoXDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= M2\0c|IxPzNzM{W1
SK-OV-3 MnLCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{DFblQ5KGh? M{XS[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNFE{KM7:TR?= M3f3eFE5PzJ{MUK3
HepG2 cells MVHDfZRwfG:6aXPpeJkh[XO|YYm= NFXieWpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyxiSVO1NF0xNjByMEG0JO69VQ>? NVPEZYp7OTdzMkewOlE>
ZR-75-1 NYL3cHFxS3m2b4TvfIlkcXS7IHHzd4F6 MULDfZRwfG:6aXPpeJkh[WejaX7zeEBbWi15NT2xJINmdGxibHnu[UwhUUN3ME2wMlAxODJ2IN88US=> M{DRW|E4OjR7NkS5
HeLa cell MVjDfZRwfG:6aXPpeJkh[XO|YYm= NUfyfYFZS3m2b4TvfIlkcXS7IHHnZYlve3RiSHXMZUBk\WyuIHzpcoUtKEmFNUC9NE4xODB|IN88US=> MnfiNVczPDl4NEm=
HCT116 cell NX:5fHhSS3m2b4TvfIlkcXS7IHHzd4F6 M1TuVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiFVEGxOkBk\WyuIHzpcoUtKEmFNUC9NE4xODB|NTFOwG0> NFG0VXAyPzJ2OU[0PS=>
KBV1 cells M2LsR2N6fG:2b4jpZ4l1gSCjc4PhfS=> MmC0O|IhcA>? MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjD2bY5jdGG|dHnu[U1z\XOrc4ThcpQhU0KYMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByNDFOwG0> MWeyNFc{OTN3NR?=
SKOV3 M4W4R2N6fG:2b4jpZ4l1gSCjc4PhfS=> MmXLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOFIh|ryP MXiyOFAyPjByMh?=
SKOV3 cells NH36SHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mni4S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAxODR{IN88US=> MmfUNlM4PzJ|MEm=
HeLa cells NXPrWGpQS3m2b4TvfIlkcXS7IHHzd4F6 M1v5V2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVEh|ryP NVvnbYd7OTl6N{m3OVg>
DU145 cells MU\DfZRwfG:6aXPpeJkh[XO|YYm= NXzPcnBCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPTRizszN NVriTFhsOjRyMU[wNFI>
DU145 cells NVPPTnU1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{Hne2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xODB3NDFOwG0> NVu0OItvOjN5N{KzNFk>
SK-N-BE NUTOUWpVWHKxbHnm[ZJifGmxbjDhd5NigQ>? NWDrcm1LPzJiaB?= NYnhfmJLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW0tvTj3CSUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVgh|ryP MV:yNlMzQTV4MR?=
NCIH460 cells NWnVb4NCS3m2b4TvfIlkcXS7IHHzd4F6 NIjoVnQ1QCCq MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2lJPDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB4IN88US=> NFnMd3AyQDNyM{i0PS=>
KB-VIN10 cells M{fnUHBzd2yrZnXyZZRqd25iYYPzZZk> M4\4UFczKGh? MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHzzJI93\XJvZYjwdoV{e2mwZzDQMYdxKDF5MD;NSHIyKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDhd5NigSxiSVO1NF0xNjByMEeg{txO NH64SJgzOTZ2MUewNC=>
HCT116 cells MV\DfZRwfG:6aXPpeJkh[XO|YYm= M{e1TVczKGh? M4jJdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhYzOKXYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFczKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxRTBwMECwO|Qh|ryP Mo\2NlE6PTV2NUS=
DU145 cells M173XGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlPWOFghcA>? NYLD[lZPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO MmnkNVg{ODN6NEm=
RS4:11 cells NEDrToNRem:uaX\ldoF1cW:wIHHzd4F6 Ml\UO|IhcA>? M2TCfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODB6IN88US=> NH35cZgzPTd6NU[wOS=>
HCT 116 NHTTeZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXLDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= MWqxNVcyPDZzMx?=
HeLa cells MnHPR5l1d3SxeHnjbZR6KGG|c3H5 MV:3NkBp NGPzfGNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFczKGi{czDifUBz\XOjeoXybY4h[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyPUCuNFAxQSEQvF2= MnLvNlQ3Pjl6OEi=
BNL 1ME A.7R.1 cells M2HZ[mN6fG:2b4jpZ4l1gSCjc4PhfS=> NGXDdYxEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDVkxiMV3FJGEvP1JwMTDj[YxteyxiSVO1NF0xNjByMEmg{txO MmT4NlU4QDV4MEW=
Calu6 M1vtNnBzd2yrZnXyZZRqd25iYYPzZZk> NIXXToo1QCCq MoDPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFYXz1OkBi\nSncjC0PEBpenNiYomgd5Bm[3S{b4Doc5RwdWW2comsJGlEPTB;MD6wNFA6PCEQvF2= NEG0bIMzOTd5NES5PS=>
melanoma B16 cell NH;xZmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M17aTmNwdmOnboTyZZRqd25id3jpZ4gheHKxZIXj[ZMhPTBnIHnubIljcXSrb36gc4Yh\3Kxd4ToJI9nKG23cnnu[UBu\Wyjbn;tZUBDOTZiY3XscEBtcW6nLDDJR|UxRTBwMECxJO69VQ>? Mn2wNVE4OTR4MUO=
DU145 cells MkLUR5l1d3SxeHnjbZR6KGG|c3H5 M3\GS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MW[yNFQ6Pjl{Mx?=
HCT116 cells Mm\tVJJwdGmoZYLheIlwdiCjc4PhfS=> NXvGbZFwPzJiaB?= M3[3ZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M3n0XVIyOTF{MUOw
HCT15 cells MlfnVJJwdGmoZYLheIlwdiCjc4PhfS=> NHXwd5M4OiCq MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEG1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGg{txO NVHJXW42OjFzMUKxN|A>
HL60 cells MU\Qdo9tcW[ncnH0bY9vKGG|c3H5 M4Pnd|czKGh? Mn\PRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Mo[5NlE3PjN|MUm=
A10 cells MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkPpOFghcA>? Mm[0S5Jwf3SqIHnubIljcXSrb36gc4YhemG2IFGxNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MmOyNlIxPDRzNkS=
HUVEC cells MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnoR3c1PDhiaB?= NF:1WotIem:5dHigbY5pcWKrdHnvckBw\iCKVW\FR{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MVyyNlA1PDF4NB?=
HL60 cells NFvhNFlEgXSxdH;4bYNqfHliYYPzZZk> NIPPb2k4OiCq M3;2WGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MlPMNlIyOzZ|MUK=
HL60 cells NV7Y[Jh{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MUK3NkBp M2LWfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M3XjVlIzPTd6MUGx
NCI-H522 cells NFnSNppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MornOFghcA>? MorQS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh3MkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NGL3WXQzOjl6MkGyNi=>
MDA-MB-435 cells NEjvRXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVW0PEBp NV\JOldyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NWiwd3hMOjJ7OEKxNlI>
OVCAR3 NILlboVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmTZOFghcA>? M3TvbGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> NGj5RlgzOjl6MkGyNi=>
NCI/ADR-RES cells Ml33S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2rJWFQ5KGh? NW\q[5hQT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLL1HEVk1TTVNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MnT4NlI6QDJzMkK=
PC3 cells M{Hjdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYTlWFc6PDhiaB?= MX7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NU\q[FVbOjJ7OEKxNlI>
DU145 cells NGWxXFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M13zNFQ5KGh? NWrI[ZRVT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> M4\WWFIzQTh{MUKy
MDA-MB-231 cells NUL0WXNzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml3zOFghcA>? NHe5WGJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP MVuyNlk5OjF{Mh?=
CEM cells NVnXS2xxS3m2b4TvfIlkcXS7IHHzd4F6 MVu3NkBp MmnlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MY[yNlY4PjJ2Nx?=
HCT116 cells NYS2b41WS3m2b4TvfIlkcXS7IHHzd4F6 NVLucXRSPzJiaB?= MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MUOyNlY4PjJ2Nx?=
MDA-MB-435 cells MXXDfZRwfG:6aXPpeJkh[XO|YYm= M1XOdlczKGh? NXO0[Gh1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NEXnU3EzOjZ5NkK0Oy=>
HaCaT cells NHW3O4RRem:uaX\ldoF1cW:wIHHzd4F6 MoflRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NYnQfplbOjNyNkO0NFE>
HL60 cells M1LCWHBzd2yrZnXyZZRqd25iYYPzZZk> NET6fFk4OiCq M{nsdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MofXNlMyOTdzN{G=
HL60 cells Mm\yVJJwdGmoZYLheIlwdiCjc4PhfS=> NWjqTGNvPzJiaB?= MkPnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSBqMz2oOEw2NWSrbXX0bJltfGirYYrvcE0zNXmuKT2yMFUu\GmyaHXufYx1\XS{YYrvcIl2dSCkcn;tbYRmKHSnc4SsJGlEPTB;MD6wNFEh|ryP NFLHdJkzPTd6NU[wOS=>
HT-29 NF;KcmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4Lvd2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NX6zSW13OjV4OEmxNVE>
HL60 cells Ml7DVJJwdGmoZYLheIlwdiCjc4PhfS=> NFq0Rpg4OiCq M4fJUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M2jyelIxPDJyNEO5
Hs578T cells MkfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVm0PEBp NHq0N2JIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJezV5OGSgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NWfXNmx[OjJ7OEKxNlI>
HL60 cells NHv6RlZEgXSxdH;4bYNqfHliYYPzZZk> MWK3NkBp NWH0e5FtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> NGnSTHgzOzR2NUS5Oi=>
SKOV3 cells MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NI\2VmxIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0:YMzDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Mnz2NlU3QDlzMUG=
MDA-MB-468 cells MofqR5l1d3SxeHnjbZR6KGG|c3H5 NWnBSGFrPCCmYYnz M37NZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNDDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNVEh|ryP NIPDUmozPDJzMEWwNy=>
MCF7 cells MWfQdo9tcW[ncnH0bY9vKGG|c3H5 MUG3NkBp NGrKOJdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFzMTFOwG0> NHHBe5kzOjN{OUW2NS=>
H460 MmXxR5l1d3SxeHnjbZR6KGG|c3H5 NXHJPHJlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIITld5QtKEmFNUC9NE4xODF{IN88US=> NWLDVHN4OTh5OEOyNFc>
H460 NIeyVZBRem:uaX\ldoF1cW:wIHHzd4F6 M1TYUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczygTWM2OD1yLkCwNVI1KM7:TR?= MmTSNVY4OjJ4M{O=
NCI-H460 cells M3nVZmN6fG:2b4jpZ4l1gSCjc4PhfS=> MV63NkBp MX;DfZRwfG:6aXOgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjD0[ZN1NCCLQ{WwQVAvODBzMzFOwG0> NVfnZm46OTh|OU[4OVc>
OVCAR8 cells NIW4NXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLoPVYhcA>? M3jTdWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCxdnXy[ZhxemW|c3nu[{BRNWeueXPvdJJwfGWrbjDh[pRmeiB7NjDodpMtKEmFNUC9NE4xODF|IN88US=> NF7kTlEzOjB2NEG2OC=>
NCI/ADR-RES cells NUnzdHQzS3m2b4TvfIlkcXS7IHHzd4F6 M2jQ[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS:DRGKtVmVUKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeTygTWM2OD1yLkCwNVMh|ryP M13CT|I{OjF2NEWy
OVCAR8 cells NGj1ZmlEgXSxdH;4bYNqfHliYYPzZZk> M{fmO|k3KGh? MofnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDl4IHjyd{BjgSCJaXXtd4Ehe3SjaX7pcocu[mG|ZXSgcIlocHRibXnjdo9{[2:yeTygTWM2OD1yLkCwNVMh|ryP M2\DTlI2ODJ3OUmx
NCI/ADR-RES cells MYLDfZRwfG:6aXPpeJkh[XO|YYm= NXT3N2JvQTZiaB?= MoTDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgPVYhcHK|IHL5JGdq\W2|YTDzeIFqdmmwZz3iZZNm\CCuaXfoeEBucWO{b4Pjc5B6NCCLQ{WwQVAvODBzMzFOwG0> M3PGOVI2ODJ3OUmx
OVCAR8 cells MkLXR5l1d3SxeHnjbZR6KGG|c3H5 NVTl[mQ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWK4JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDhd5NigSxiSVO1NF0xNjByMUOg{txO NYPoS296OjN{MUS0OVI>
HuTu 80 cells NVv1S2hTWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkX4O|IhcA>? M{TIc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJGh2XHViOECgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMUO3JO69VQ>? NEDMR2IzOjN{OUW2NS=>
K562 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= MmDVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{whUUN3ME2wMlAxOTRizszN M1\nbVE6QDN5NUm0
NCI/ADR (MDR) cells M33MT2Z2dmO2aX;uJIF{e2G7 M{S4fWNmdGxiY4njcIUh[XK{ZYP0JIlvKE6FST;BSHIhME2GUjmgZ4VtdHNiYomgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WsJGlEPTB;MD6wNFE2KM7:TR?= MlPBNVY{PzdzOEe=
HUVEC NX62bVdqWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVHzRW84SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyxiSVO1NF0xNjByMUWg{txO NV7LZ4NTOTZ5MkK2N|M>
KB cell MUDQdo9tcW[ncnH0bY9vKGG|c3H5 MkjVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQjDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= M{TOPVE4ODN2MUS3
KB-VIN10 cell NGOx[JBRem:uaX\ldoF1cW:wIHHzd4F6 MnTZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQj3WTW4yOCClZXzsJIxqdmViYomgcYV1cHmuZX7lJIJtfWViZInlJIF{e2G7LDDJR|UxRTBwMECxOUDPxE1? NUXOeFRqOTdyM{SxOFc>
Human SH-SY5Y neuroblastoma cells NY\zXI5ZTnWwY4Tpc44h[XO|YYm= MUHJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCKdX3hckBUUC2VWUXZJI5mfXKxYnzhd5RwdWFiY3XscJMtKEmFNUC9NE4xODF3IN88US=> MWqxOVk3Ozd{Mh?=
SW620 cells M3n6OnBzd2yrZnXyZZRqd25iYYPzZZk> MVm3NkBp M1vpeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNYPjJyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF3MjFOwG0> NEjRVVczOjN{OUW2NS=>
Molt4/C8 cells M{LCOXBzd2yrZnXyZZRqd25iYYPzZZk> M3zwXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMtKEmFNUC9NE4xODF4IN88US=> NVnPUmhJOTdyM{SxOVA>
ACHN cell M{fGRXBzd2yrZnXyZZRqd25iYYPzZZk> M1jLbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[JJ2\yC{ZYPpd5RidnRiQVPIUkBk\WyuIHzpcoUh\XiycnXzd4lv\yCPRGKxJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> M3GxTFE4Ojh4M{mz
Molt4/C8 cells MVjQdo9tcW[ncnH0bY9vKGG|c3H5 NEXKe4o{KGSjeYO= MXrBcpRqeHKxbHnm[ZJifGm4ZTDl[oZm[3RiYXfhbY5{fCCqdX3hckBOd2y2ND;DPEBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUC9NE4xODF4IN88US=> NH\lUnUyPzRzOU[wOy=>

... Click to View More Cell Line Experimental Data

体内研究 在NT2和MDA-MB-231乳腺肿瘤模型中,Combretastatin A4 (100 mg/kg, i.p.)诱导脂质R1显著减少,并通过电子顺磁共振(EPR)血氧定量法测得pO2下降。[2] Combretastatin A4 (100 mg/kg, i.p.)显著减少雄性NMRI小鼠的Ktrans[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

使用 LC-MS/MS 的竞争性结合试验:

Colchicine (1.2 μ M)与微管蛋白(1.3 mg/mL)在培养缓冲液(80 mM PIPES,2.0 mM MgCl2,0.5 mM EGTA,pH 6.9)中于37℃下培养1小时。使用不同浓度(0.1− 125 μ M)的Combretastatin A4与原本结合微管蛋白的colchicine竞争。培育后,得到滤液。类似物抑制秋水仙碱结合的能力表示为不存在任何竞争物的对照组的百分比。
细胞实验:[1]
- 合并
  • Cell lines: MDA-MB-231,A549,和 Hela 细胞
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231,A549,和HeLa细胞在DMEM培养基(115 units/mL 青霉素G,115 μg/mL 链霉素,和10%胎牛血清)中生长。细胞(5000 细胞/孔)接种于包含50 μL生长培养基的96孔板,培养24小时。移除培养基后,将100 μL包含不同浓度单个类似化合物的新鲜培养基加入到每个孔中,在37 ℃下培养72小时。培养24小时后,细胞中增补50 μL溶于DMSO(每个制剂中少于0.25%)的类似化合物。培养72小时后,加入20 μL刃天青培养2小时,然后在560 nm (激发波长)和590 nm (发射波长)下使用Victor微量滴定板荧光剂记录荧光。对照组为用最大量DMSO (0.25%)处理的细胞,活性为100%,IC50定义为与对照组相比,抑制50%细胞增殖的化合物浓度。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 负荷 NT2 和 MDA-MB-231肿瘤的 FVB/N或裸的NMRI雄性小鼠
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+50% PEG 300+ddH2O
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 316.35
化学式

C18H20O5

CAS号 117048-59-6
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to make solution for in vivo IP injection?

  • 回答:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Combretastatin A4 | Combretastatin A4供应商 | 采购Combretastatin A4 | Combretastatin A4价格 | Combretastatin A4生产 | 订购Combretastatin A4 | Combretastatin A4代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID